Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Болезнь Пейрони

Литература

  1. Щеплев П.А., Гарин Н.Н., Данилов И.А. и др. Болезнь Пейрони. — М.: ИД «АБВ-пресс», 2012. — 216 с.
  2. Schwarzer U., Sommer F., Klotz T. et al. The prevalence of Peyronie’s disease: results of a large survey //B.J. U. Int — 2001. — Vol. 88 (7). — 727–730. http:// www.ncbi.nlm.nih.gov/pubmed/11890244
  3. Rhoden E.L., Teloken C., Ting H.Y. et al. Prevalence of Peyronie’s disease in men over 50-y-old from Southern Brazil //Int.J. Impot. Res. — 2001. — Vol. 13 (5). — 291–293. http://www.ncbi.nlm.nih.gov/pubmed/11890516
  4. Mulhall J.P., Creech S.D., Boorjian S.A. et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening //J. Urol. — 2004. — Vol. 171 (6 Pt 1). — P. 2350– 2353. http://www.ncbi.nlm.nih.gov/pubmed/15126819
  5. La Pera G., Pescatori E.S., Calabrese M. et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50–69 years //Eur. Urol. — 2001. — Vol. 40. — P. 525–530. http:// www.ncbi.nlm.nih.gov/pubmed/11752860
  6. Kumar B., Narang T., Gupta S. et al. A clinico-aetiological and ultrasonographic study of Peyronie’s disease. Sex Health 2006 May; 3 (2):113–118 http://www. ncbi.nlm.nih.gov/pubmed/16800397
  7. Lindsay M.B., Schain D.M., Grambsch P. et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991 Oct; 146 (4):1007–9. http://www.ncbi.nlm.nih.gov/pubmed/1895413
  8. Sommer F., Schwarzer U., Wassmer G. et al. Epidemiology of Peyronie’s disease. Int J Impot Res 2002 Oct; 14 (5):379–383. http://www.ncbi.nlm.nih.gov/ pubmed/12454689
  9. Pryor J.P., Ralph D.J. Clinical presentations of Peyronie’s disease //Int.J. Impot. Res. — 2002. — Vol. 14. — P. 414–417.
  10. Rhoden E.L., Riedner C.E., Fuchs S.C. et al. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie’s disease. J Sex Med 2010 Apr; 7 (4 Pt 1):1529–1537. http://www.ncbi.nlm.nih. gov/ pubmed/19912489
  11. Kadioglu A., Tefekli A., Erol B. et al. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002 Sep; 168 (3):1075–1079.
  12. Ralph D.J., Al-Akraa M., Pryor J.P. The Nesbitis operation for Peyronie’sdisease: 16-year experience //J. Urol. — 1995. — Vol. 154. — P. 1362–1372.
  13. Hinman F. Etiologic factors in Peyronie’s disease //Urol. Int. — 1980. — Vol. 35. — P. 407–413.
  14. Pryor J.P. Peyronie’s disease and impotence //Acta Urol. Belg. — 1988. — Vol. 56. — P. 317–321.
  15. Gasior B.L., Levine F.J., Howannesian A. et al. Plaque-associated corporalveno- occlusive dysfunction in idiopathic Peyronie’s disease: A pharmacavernosometric and pharmacavernosographic study //World J. Urol. — 1990. — Vol. 8. — P. 90–96.
  16. Desai K.M., Gingell J.C. Out-patient assessment of penile curvature // Br.J. Urol. — 1987. — Vol. 60. — P. 470–471.
  17. Kelami A. Classification of congenital and acquired penile deviation //Urol. Int. — 1983. — Vol. 38. —P. 229–233.
  18. Руководство по урологии / под ред. Н.А. Лопаткина. — М.: Медицина, 1998. — Т. 3. — С. 632.
  19. Incrocci L., Slob A.K., Hop W.C. et al. Low-dose radiotherapyin 179 patients with Peyronie’s disease: treatment, outcome and current sexual function // Int.J. Radiat. Oncol. Biol. Phys. — 2000. — Vol. 47. — P. 1353–1356.
  20. Pryor J.P., Farell C.F. Controlled clinical trial of Vitamin E in Peyronie’s dis- ease //Prog. Reprod. Biol. — 1983. — Vol. 9. — P. 41–45.
  21. Shah P.J.R., Green N.A., Adib R.S. et al. A multicentre double-blind controlled clinical trial of potassium para-amino-benzoate (POTABA1) in Peyronie’s dis- ease //Progr. Reprod. Biol. Med. — 1983. — Vol. 9. — P. 61–67.
  22. Weidner W., Hauck E.W., Schnitker J. Potassium paraaminobenzoate (POTA- BA) in the treatment of Peyronie’s disease: a prospective, placebocontrolled, randomized study //Eur. Urol. — 2005. — Apr. — Vol. 47 (4). — P. 530–535. http://www.ncbi.nlm.nih.gov/pubmed/15774254
  23. Ralph D.J., Brooks M.D., Bottazzo G.F. et al. The treatment of Peyronie’s disease with tamoxifen //Br.J. Urol. — 1992. — Dec. — Vol. 70 (6). — P. 648–651. http://www.ncbi.nlm.nih.gov/pubmed/1486392
  24. Teloken C., Rhoden E.L., Grazziotin T.M. et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease //J. Urol. — 1999. — Dec. — Vol. 162 (6). — P. 2003–2005. http://www.ncbi.nlm.nih.gov/pubmed/10569556
  25. Kadioglu A., Tefekli A., Koksal T. et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome // Int.J. Impot. Res. — 2000. — Jun. — Vol. 12 (3). — P. 169–175. http:// www. ncbi.nlm.nih.gov/pubmed/11045911
  26. Akkus E., Carrier S., Rehman J. et al. Is colchicine effective in Peyronie’s disease? A pilot study //Urology. — 1994. — Aug. — Vol. 44 (2). — P. 291–295. http:// www.ncbi.nlm.nih.gov/pubmed/8048212
  27. Akman T., Sanli O., Uluocak N. et al. The most commonly altered type of Peyronie’s disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side //Andrologia. — 2011. — Feb. — Vol. 43 (1). — P. 28–33. http://www.ncbi.nlm.nih.gov/pubmed/21219379
  28. Prieto Castro R.M., Leva Vallejo M.E., Regueiro Lopez J.C. et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease //B.J. U. Int. — 2003. — Apr. — 91 (6). — P. 522–524. http://www.ncbi. nlm.nih. gov/pubmed/12656907
  29. Brant W.O., Dean R.C., Lue T.F. Treatment of Peyronie’s disease with oral pentoxifylline //Nat. Clin. Pract. Urol. — 2006. — Feb. — Vol. 3 (2). — P. 111– 115; quiz 6. http://www.ncbi.nlm.nih.gov/pubmed/16470210
  30. Smith J.F., Shindel A.W., Huang Y.C. et al. Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease //Asian J. Androl. — 2011. — Mar. — Vol. 13 (2). — P. 322–325. http://www.ncbi.nlm.nih.gov/ pubmed/21102473
  31. Ferrini M.G., Kovanecz I., Nolazco G. et al. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease //B.J. U. Int. — 2006. — Mar. — Vol. 97 (3). — P. 625–633. http://www. ncbi.nlm.nih.gov/pubmed/16469038
  32. Cipollone G., Nicolai M., Mastroprimiano G. et al. [Betamethasone versus placebo in Peyronie’s disease] //Arch. Ital. Urol. Androl. — 1998. — Sep. — Vol. 70 (4). — P. 165–168. http://www.ncbi.nlm.nih.gov/pubmed/9823662
  33. Levine L.A., Goldman K.E., Greenfield J.M. Experience with intraplaque injection of verapamil for Peyronie’s disease //J. Urol. — 2002. — Aug. — Vol. 168 (2). — P. 621–625; discussion 5–6. http://www.ncbi.nlm.nih.gov/ pubmed/12131321
  34. Anderson M.S., Shankey T.V., Lubrano T. et al. Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents //Int.J. Impot. Res. — 2000. — Sep. — Vol. 12. — Suppl. 3. — P. S25–31. http://www.ncbi.nlm.nih.gov/ pubmed/11002396
  35. Rehman J., Benet A., Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study // Urology. — 1998. — Apr. — Vol. 51 (4). — P. 620–626. http://www.ncbi.nlm.nih.gov/ pubmed/9586617
  36. Bennett N.E., Guhring P., Mulhall J.P. Intralesional verapamil prevents the progression of Peyronie’s disease //Urology. — 2007. — Jun. — Vol. 69 (6). — P. 1181–1184. http://www.ncbi.nlm.nih.gov/pubmed/17572211
  37. Cavallini G., Modenini F., Vitali G. Open preliminary randomized prospective clinical trial of efficacyand safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease //Urology. — 2007. — May. — Vol. 69 (5). — P. 950–954. http://www.ncbi.nlm.nih.gov/pubmed/17482941
  38. Shirazi M., Haghpanah A.R., Badiee M. et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study //Int. Urol. Nephrol. — 2009. — Vol. 41 (3). — P. 467–471. http://www. ncbi.nlm.nih.gov/pubmed/19199072
  39. Gelbard M.K., James K., Riach P. et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study //J. Urol. — 1993. — Jan. — Vol. 149 (1). — P. 56–58. http://www.ncbi.nlm.nih.gov/pubmed/8417217
  40. Kendirci M., Usta M.F., Matern R.V. et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie’s disease //J.Sex. Med. — 2005. — Sep. — Vol. 2 (5). — P. 709–715. http://www. ncbi.nlm.nih.gov/pubmed/16422829
  41. Hellstrom W.J., Kendirci M., Matern R. et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease //J. Urol. — 2006. — Jul. — Vol. 176 (1). — P. 394–398. http://www. ncbi.nlm.nih.gov/pubmed/16753449
  42. Fitch W.P. 3rd, Easterling W.J., Talbert R.L. et al. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease--a placebo-controlled pilot study //J.Sex. Med. — 2007. — Mar. — Vol. 4 (2). — P. 477–484. http://www.ncbi.nlm.nih.gov/pubmed/17367443
  43. Di Stasi S.M., Giannantoni A., Capelli G. et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease //B.J. U. Int. — 2003. — Jun. — Vol. 91 (9). — P. 825–829. http://www.ncbi.nlm. nih. gov/pubmed/12780842
  44. Riedl C.R., Plas E., Engelhardt P. et al. Iontophoresis for treatment of Peyronie’s disease //J. Urol. — 2000. — Jan. — Vol. 163 (1). — P. 95–99. http:// www.ncbi. nlm.nih.gov/pubmed/10604323
  45. Tuygun C., Ozok U.H., Gucuk A. et al. The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie’s disease //Int. Urol. Nephrol. — 2009. — Vol. 41 (1). — P. 113–118. http://www.ncbi.nlm.nih.gov/pubmed/18592390
  46. Di Stasi S.M., Giannantoni A., Stephen R.L. et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease //J. Urol. — 2004. — Apr. — Vol. 171 (4). — P. 1605–1608. http://www.ncbi.nlm.nih.gov/pubmed/15017231
  47. Greenfield J.M., Shah S.J., Levine L.A. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial //J. Urol. — 2007. — Mar. — Vol. 177 (3). — P. 972–5. http:// www.ncbi. nlm.nih.gov/pubmed/17296390
  48. Strebel R.T., Suter S., Sautter T. et al. Extracorporeal shockwave therapy for Peyronie’s disease does not correct penile deformity //Int.J. Impot. Res. — 2004. — Oct. — Vol. 16 (5). — P. 448–451. http://www.ncbi.nlm.nih.gov/ pubmed/14973523
  49. Hauck E.W., Hauptmann A., Bschleipfer T. et al. Questionable efficacy of extracorporeal shock wave therapy for Peyronie’s disease: results of a prospective approach //J. Urol. — 2004. — Jan. — Vol. 171 (1). — P. 296–299. http://www. ncbi.nlm.nih.gov/pubmed/14665898
  50. SrirangamS.J.,ManikandanR.,HussainJ.etal.Long-termresultsofextracorporeal shockwave therapy for Peyronie’s disease //J. Endourol. — 2006. — Nov. — Vol. 20 (11). — P. 880–884. http://www.ncbi.nlm.nih.gov/pubmed/17144855
  51. Palmieri A., Imbimbo C., Longo N. et al. A first prospective, randomized, double-blind, placebocontrolled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease //Eur. Urol. — 2009. — Aug. — Vol. 56 (2). — P. 363–369. http://www.ncbi.nlm.nih.gov/ pubmed/19473751
  52. Levine L.A., Newell M., Taylor F.L. Penile traction therapy for treatment of Peyronie’s disease: a singlecenter pilot study //J.Sex. Med. — 2008. — Jun. — Vol. 5 (6). — P. 1468–1473. http://www.ncbi.nlm.nih.gov/pubmed/18373527
  53. Gontero P., Di Marco M., Giubilei G. et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study //J.Sex. Med. — 2009. — Feb. — Vol. 6 (2). — P. 558–566. http://www.ncbi.nlm.nih.gov/pubmed/19138361
  54. Raheem A.A., Garaffa G., Raheem T.A. et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease //B.J. U. Int. — 2010. — Oct. — Vol. 106 (8). — P. 1178–80. http://www.ncbi.nlm.nih.gov/ pubmed/20438558
  55. Nesbit R. Congenital curvature of the phallus: Report of three cases with description of corrective operation //J. Urol. — 1965. — Feb. — Vol. 93. — P. 230–2.
  56. Pryor J.P., Fitzpatrick J.M. A new approach to the correction of the penile deformity in Peyronie’s disease //J Urol. — 1979. — Nov. — Vol. 122 (5). — P. 622–623. http://www.ncbi.nlm.nih.gov/pubmed/501814
  57. Langston J.P., Carson C.C. 3rd. Peyronie disease: plication or grafting //Urol. Clin. North. Am. — 2011. — Vol. 38. — P. 207–216.
  58. Pryor J.P. Correction of penile curvature and Peyronie’s disease: why I prefer the Nesbit technique //Int.J. Impot. Res. — 1998. — Jun. — Vol. 10 (2). — P. 129– 131. http://www.ncbi.nlm.nih.gov/pubmed/9647952
  59. Lemberger R.J., Bishop M.C., Bates C.P. Nesbit’s operation for Peyronie’s disease //Br.J. Urol. — 1984. — Dec. — Vol. 56 (6). — P. 721–723. http://www. ncbi.nlm.nih.gov/pubmed/6534497
  60. Sassine A.M., Wespes E., Schulman C.C. Modified corporoplasty for penile curvature: 10 years’ experience //Urology. — 1994. — Sep. — Vol. 44 (3). — P. 419–321. http://www.ncbi.nlm.nih.gov/pubmed/8073558
  61. Licht M.R., Lewis R.W. Modified Nesbit procedure for the treatment of Peyronie’s disease: a comparative outcome analysis //J. Urol. — 1997. — Aug. — Vol. 158 (2). — P. 460–463. http://www.ncbi.nlm.nih.gov/pubmed/9224323
  62. Yachia D. Modified corporoplasty for the treatment of penile curvature //J. Urol. — 1990. — Jan. — Vol. 143 (1). — P. 80–82. http://www. ncbi.nlm.nih.gov/ pubmed/2294269
  63. Essed E., Schroeder F.H. New surgical treatment for Peyronie disease // Urology. — 1985. — Jun. — Vol. 25 (6). — P. 582–587. http://www.ncbi.nlm. nih. gov/pubmed/4012950
  64. Ebbehoj J., Metz P. New operation for «krummerik» (penile curvature) //Urology. — 1985. — Jul. — Vol. 26 (1). — P. 76–78. http://www.ncbi.nlm.nih.gov/ pubmed/3892851
  65. Kadioglu A., Akman T., Sanli O. et al. Surgical treatment of Peyronie’s disease: a critical analysis //Eur. Urol. — 2006. — Aug. — Vol. 50 (2). — P. 235– http:// www.ncbi.nlm.nih.gov/pubmed/16716495
  66. Montorsi F., Salonia A., Maga T. et al. Evidence based assessment of longterm results of plaque incision and vein grafting for Peyronie’s disease //J. Urol. — 2000. — Jun. — Vol. 163 (6). — P. 1704–1708. http://www.ncbi.nlm.nih.gov/ pubmed/10799165
  67. Kadioglu A., Tefekli A., Usta M. et al. Surgical treatment of Peyronie’s disease with incision and venous patch technique //Int.J. Impot. Res. — 1999. — Apr. — Vol. 11 (2). — P. 75–81. http://www.ncbi.nlm.nih.gov/pubmed/10356666
  68. El-Sakka A.I., Rashwan H.M., Lue T.F. Venous patch graft for Peyronie’s disease. Part II: outcome analysis //J. Urol. — 1998. — Dec. — Vol. 160 (6 Pt 1). — P. 2050–2053. http://www.ncbi.nlm.nih.gov/pubmed/9817321
  69. Hatzichristou D.G., Hatzimouratidis K., Apostolidis A. et al. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and longterm results //J. Urol. — 2002. — Mar. — Vol. 167 (3). — P. 1367–1370. http:// www.ncbi.nlm.nih.gov/pubmed/11832734
  70. Das S. Peyronie’s disease: excision and autografting with tunica vaginalis //J. Urol. — 1980. — Dec. — Vol. 124 (6). — P. 818–819. http://www. ncbi.nlm.nih. gov/pubmed/7441830
  71. Gelbard M.K., Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts //J. Urol. — 1991. — Apr. — Vol. 145 (4). — P. 772–776. http://www.ncbi.nlm.nih.gov/pubmed/2005698
  72. Cormio L., Zucchi A., Lorusso F. et al. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa //Eur. Urol. — 2009. — Jun. — Vol. 55 (6). — P. 1469–1475. http://www.ncbi.nlm.nih.gov/pubmed/19084325 22 FEBRUARY 2012
  73. Taylor F.L., Levine L.A. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up //J.Sex. Med. — 2008. — Sep. — Vol. 5 (9). — P. 2221–2228. http:// www.ncbi.nlm.nih.gov/pubmed/18637996
  74. Burnett A.L. Fascia lata in penile reconstructive surgery: a reappraisal of the fascia lata graft //Plast. Reconstr. Surg. — 1997. — Apr. — Vol. 99 (4). — P. 1061– 1067. http://www.ncbi.nlm.nih.gov/pubmed/9091903
  75. Fallon B. Cadaveric dura mater graft for correction of penile curvature in Peyronie disease //Urology. — 1990. — Feb. — Vol. 35 (2). — P. 127–129. http:// www.ncbi.nlm.nih.gov/pubmed/2305535
  76. Leungwattanakij S., Bivalacqua T.J., Yang D.Y. et al. Comparison of cadaveric pericardial, dermal, vein, and synthetic grafts for tunica albuginea substitution using a rat model //B.J. U. Int. — 2003. — Jul. — Vol. 92 (1). — P. 119–124. http:// www.ncbi.nlm.nih.gov/pubmed/12823395
  77. Knoll L.D. Use of porcine small intestinal submucosal graft in the surgical management of Peyronie’s disease //Urology. — 2001. — Apr. — Vol. 57 (4). — P. 753–757. http://www.ncbi.nlm.nih.gov/pubmed/11306396
  78. Bokarica P., Parazajder J., Mazuran B. et al. Surgical treatment of Peyronie’s disease based on penile length and degree of curvature //Int.J. Impot. Res. — 2005. — Mar.— Apr. — 17 (2). — Vol. 170–174. http://www.ncbi.nlm.nih.gov/ pubmed/15215882
  79. Faerber G.J., Konnak J.W. Results of combined Nesbit penile plication with plaque incision and placement of Dacron patch in patients with severe Peyronie’s disease //J. Urol. — 1993. — May. — Vol. 149 (5 Pt 2). — P. 1319–1320. http:// www.ncbi.nlm.nih.gov/pubmed/8479026
  80. Egydio P.H., Lucon A.M., Arap S. A single relaxing incision to correct different types of penile curvature: surgical technique based on geometrical principles //B.J. U. Int. — 2004. — Nov. — Vol. 94 (7). — P. 1147–1157. http:// www.ncbi. nlm.nih.gov/pubmed/15541152
  81. Chun J.L., McGregor A., Krishnan R. et al. A comparison of dermal and cadaveric pericardial grafts in the modified Horton-Devine procedure for Peyronie’s disease //J. Urol. — 2001. — Jul. — Vol. 166 (1). — P. 185–1888. http://www.ncbi. nlm.nih.gov/pubmed/11435853
  82. Chung E., Clendinning E., Lessard L. et al. Five-year follow-up of Peyronie’s graft surgery: outcomes and patient satisfaction //J.Sex. Med. — 2011. — Feb. — Vol. 8 (2). — P. 594–600. http://www.ncbi.nlm.nih.gov/pubmed/21054805
  83. Mulhall J., Anderson M., Parker M. A surgical algorithm for men with com- bined Peyronie’s disease and erectile dysfunction: functional and satisfac- tion outcomes //J.Sex. Med. — 2005. — Jan. — Vol. 2 (1). — P. 132–138. http://www. ncbi.nlm.nih.gov/pubmed/16422916
  84. Taylor F.L., Levine L.A. Peyronie’s Disease //Urol. Clin. North. Am. — 2007. — Nov. — Vol. 34 (4). — P. 517–534. http://www.ncbi.nlm.nih.gov/ pubmed/17983892
  85. Montorsi F., Guazzoni G., Barbieri L. et al. AMS 700 CX inflatable penile im- plants for Peyronie’s disease: functional results, morbidity and patient-partner satisfaction //Int.J. Impot. Res. — 1996. — Jun. — Vol. 8 (2). — P. 81–85; dis- cussion 5–6. http://www.ncbi.nlm.nih.gov/pubmed/8858396
  86. Wilson S.K. Surgical techniques: modeling technique for penile curvature // J.Sex. Med. — 2007. — Jan. — Vol. 4 (1). — P. 231–234. http://www.ncbi.nlm. nih. gov/pubmed/17233788
  87. Wilson S.K., Delk J.R. 2nd. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis //J. Urol. — 1994. — Oct. — Vol. 152 (4). — P. 1121–1123. http://www.ncbi.nlm.nih.gov/pubmed/8072079
  88. Carson C.C. Penile prosthesis implantation in the treatment of Peyronie’s dis- ease //Int.J. Impot. Res. — 1998. — Jun. — 10 (2). — Vol. 125–128. http:// www. ncbi.nlm.nih.gov/pubmed/9647951
  89. Montague D.K., Angermeier K.W., Lakin M.M. et al. AMS 3-piece inflatable pe- nile prosthesis implantation in men with Peyronie’s disease: comparison of CX and Ultrex cylinders //J. Urol. — 1996. — Nov. — Vol. 156 (5). — P. 1633–1635. http://www.ncbi.nlm.nih.gov/pubmed/8863557
  90. Chaudhary M., Sheikh N., Asterling S. et al. Peyronie’s disease with erectile dysfunction: penile modelling over inflatable penile prostheses //Urology. — 2005. — Apr — Vol. 65 (4). — P. 760–764. http://www.ncbi.nlm.nih.gov/ pubmed/15833523
  91. http://uroweb.org/fileadmin/guidelines/Guidelines_2014_5_June_2014.pdf

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*